A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-26

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tislelizumab as Cross-line Treatment for Advanced NSCLC

NCT05192681

Advanced Non-small-cell Lung Cancer

UNKNOWN PHASE2

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

NCT05228496

Lung Cancer, Small Cell

UNKNOWN PHASE2

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04921358

Non-Small Cell Lung Cancer (NSCLC)

TERMINATED PHASE3

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

NCT01836679

Non-small-cell Lung Cancer

COMPLETED PHASE2

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

NCT07120282

Lung Cancer (NSCLC)

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tucidinostat Combined with Tislelizumab

Subjects receive Tucidinostat 30mg orally biw and Tislelizumab 200 mg intravenously (IV) Q3W.

Group Type EXPERIMENTAL

Tucidinostat

Intervention Type DRUG

30mg orally BIW

Tislelizumab

Intervention Type DRUG

200 mg intravenously (IV) Q3W

Tislelizumab

Subjects receive Tislelizumab 200 mg intravenously (IV) Q3W.

Group Type ACTIVE_COMPARATOR

Tislelizumab

Intervention Type DRUG

200 mg intravenously (IV) Q3W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tucidinostat

30mg orally BIW

Intervention Type DRUG

Tislelizumab

200 mg intravenously (IV) Q3W

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chidamide CS055

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years, Male or female.
2. Histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic (stage IIIB-IV) NSCLC.
3. Must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
4. Must have positive PD-L1 expression in tumor tissue.
5. ECOG performance status of 0 or 1.
6. Must Have ≥1 measurable target lesion as defined by RECIST v.1.1.
7. Must have adequate organ function.
8. Life expectancy ≥ 12 weeks.
9. Signed informed consent form (ICF).

Exclusion Criteria

1. With EGFR or ALK gene mutation.
2. Received prior targeted therapy.
3. Prior use of HDAC inhibitor.
4. Received prior therapies targeting PD-1, PD-L1, CTLA4, or any other immune checkpoint pathway.
5. Received any anti-tumor therapy or investigational agent and device within 28 days before the first dose of study treatment.
6. Received radiotherapy within 2 weeks or thoracic radiation \>30Gy within 6 months before the first dose of study treatment.
7. Received systemic immunosuppressive drugs within 28 days before the first dose of study treatment. Inhaled or topical steroids and physiological dose of systemic glucocorticoid (≤10 mg daily prednisone equivalents) are permitted.
8. Received systemic immunostimulatory drugs within 28 days before the first dose of study treatment.
9. Received a live vaccine within 28 days before the first dose of study treatment or planned to receive during the study period. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; and COVID-19 vaccine also are allowed.
10. Received major surgery within 28 days before the first dose of study treatment.
11. Has not recovered ( ≤ Grade 1 defined by CTCAE V5.0) from AEs due to prior anti-cancer therapy.
12. Has symptomatic and untreated central nervous system (CNS) metastases.
13. Has hydrothorax and ascites with obvious symptoms or requiring repeated drainage within 1 month before the first dose of study treatment.
14. Uncontrollable or major cardiovascular and cerebrovascular disease.
15. History of hemoptysis within 2 weeks or active bleeding within 2 months before the first dose of study treatment; or subject who is taking anticoagulants, or subject with clear high-risk bleeding tendency during the screening period.
16. History of serious thromboembolism within 6 months before the first dose of study treatment.
17. Suspected interstitial lung disease (ILD) or pulmonary fibrosis or pulmonary inflammation requiring treatment; or history of lung disease treated with oral or intravenous steroids within 6 months before the first dose of study treatment.
18. Obvious gastrointestinal abnormalities during the screening period, which may affect the intake, transport or absorption of drugs.
19. Urinary protein ≥ 2+ and quantitative urinary protein ≥ 1g/24 h during the screening period.
20. Active infection requiring intravenous therapy; or severe infection within 28 days before the first dose of study treatment.
21. Known active pulmonary tuberculosis, or subject who is receiving antituberculous treatment or having received antituberculous treatment within 1 year before the first dose of study treatment.
22. Active hepatitis B or hepatitis C.
23. HIV positive or history of AIDS or other serious infectious diseases.
24. History of malignant tumor.
25. Active autoimmune diseases during the screening period, and have received systemic treatment within 2 years before the first dose of study treatment.
26. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
27. Contraindications to any of the study drug ingredients.
28. History of hypersensitivity to monoclonal antibody, Chidamide, study drugs, or any of its excipients.
29. History of alcohol or drug abuse.
30. Unwilling or unable to comply with procedures required in this protocol.
31. Pregnant or breast-feeding women. Male/Female is unwilling or unable to use a highly effective method of birth control.

33\. Any condition not suitable for participating in the trial in the opinion of the Investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No